Search

Your search keyword '"Robertson, Michael N."' showing total 284 results
Start Over Author "Robertson, Michael N."
284 results on '"Robertson, Michael N."'

2. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial

Author

Molina, Jean-Michel, Yazdanpanah, Yazdan, Afani Saud, Alejandro, Bettacchi, Christopher, Chahin Anania, Carolina, DeJesus, Edwin, Olsen Klopfer, Stephanie, Grandhi, Anjana, Eves, Karen, Robertson, Michael N, Correll, Todd, Hwang, Carey, Hanna, George J, and Sklar, Peter

Published
2021
Full Text
View/download PDF

3. Development of ZEPATIER®

Author

Robertson, Michael N., Barr, Eliav, Bernstein, Peter R., Series Editor, Garner, Amanda L., Series Editor, Georg, Gunda I., Series Editor, Lowe, John A., Series Editor, Meanwell, Nicholas A., Series Editor, Saxena, Anil Kumar, Series Editor, Supuran, Claudiu T., Series Editor, Zhang, Ao, Series Editor, and Sofia, Michael J., editor

Published
2019
Full Text
View/download PDF

4. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials

Author

Lawitz, Eric, Buti, Maria, Vierling, John M, Almasio, Piero L, Bruno, Savino, Ruane, Peter J, Hassanein, Tarek I, Muellhaupt, Beat, Pearlman, Brian, Jancoriene, Ligita, Gao, Wei, Huang, Hsueh-Cheng, Shepherd, Aimee, Tannenbaum, Brynne, Fernsler, Doreen, Li, Jerry J, Grandhi, Anjana, Liu, Hong, Su, Feng-Hsiu, Wan, Shuyan, Dutko, Frank J, Nguyen, Bach-Yen T, Wahl, Janice, Robertson, Michael N, Barr, Eliav, Yeh, Wendy W, Plank, Rebeca M, Butterton, Joan R, and Yoshida, Eric M

Published
2017
Full Text
View/download PDF

5. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Author

Gane, Edward J, Pianko, Stephen, Roberts, Stuart K, Thompson, Alexander J, Zeuzem, Stefan, Zuckerman, Eli, Ben-Ari, Ziv, Foster, Graham R, Agarwal, Kosh, Laursen, Alex L, Gerstoft, Jan, Gao, Wei, Huang, Hsueh-Cheng, Fitzgerald, Brian, Fernsler, Doreen, Li, Jerry J, Grandhi, Anjana, Liu, Hong, Su, Feng-Hsiu, Wan, Shuyan, Zeng, Zhen, Chen, Huei-Ling, Dutko, Frank J, Nguyen, Bach-Yen T, Wahl, Janice, Robertson, Michael N, Barr, Eliav, Yeh, Wendy W, Plank, Rebeca M, Butterton, Joan R, and Esteban, Rafael

Published
2017
Full Text
View/download PDF

8. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

Author

Rockstroh, Jürgen K, Nelson, Mark, Katlama, Christine, Lalezari, Jay, Mallolas, Josep, Bloch, Mark, Matthews, Gail V, Saag, Michael S, Zamor, Philippe J, Orkin, Chloe, Gress, Jacqueline, Klopfer, Stephanie, Shaughnessy, Melissa, Wahl, Janice, Nguyen, Bach-Yen T, Barr, Eliav, Platt, Heather L, Robertson, Michael N, and Sulkowski, Mark

Published
2015
Full Text
View/download PDF

9. A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection

Author

Matthews, Randolph P., primary, Zang, Xiaowei, additional, Barrett, Stephanie E., additional, Koynov, Athanas, additional, Goodey, Adrian, additional, Heimbach, Tycho, additional, Weissler, Vanessa L., additional, Leyssens, Carlien, additional, Reynders, Tom, additional, Xu, Zhiqing, additional, Rottey, Sylvie, additional, Vargo, Ryan, additional, Robertson, Michael N., additional, Stoch, S. Aubrey, additional, and Iwamoto, Marian, additional

Published
2022
Full Text
View/download PDF

10. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study

Author

Kumada, Hiromitsu, Suzuki, Yoshiyuki, Karino, Yoshiyasu, Chayama, Kazuaki, Kawada, Norifumi, Okanoue, Takeshi, Itoh, Yoshito, Mochida, Satoshi, Toyoda, Hidenori, Yoshiji, Hitoshi, Takaki, Shintaro, Yatsuzuka, Naoyoshi, Yodoya, Etsuo, Iwasa, Takashi, Fujimoto, Go, Robertson, Michael N., Black, Stuart, Caro, Luzelena, and Wahl, Janice

Published
2017
Full Text
View/download PDF

11. Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

Author

Grebely, Jason, primary, Dore, Gregory J., additional, Altice, Frederick L., additional, Conway, Brian, additional, Litwin, Alain H., additional, Norton, Brianna L., additional, Dalgard, Olav, additional, Gane, Edward J., additional, Shibolet, Oren, additional, Nahass, Ronald, additional, Luetkemeyer, Anne F., additional, Peng, Cheng-Yuan, additional, Iser, David, additional, Gendrano, Isaias Noel, additional, Kelly, Michelle M., additional, Hwang, Peggy, additional, Asante-Appiah, Ernest, additional, Haber, Barbara A., additional, Barr, Eliav, additional, Robertson, Michael N., additional, and Platt, Heather, additional

Published
2022
Full Text
View/download PDF

13. Facilitating Next‐Generation Pre‐Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project.

Author

Parkin, Neil, Gao, Fei, Grebe, Eduard, Cutrell, Amy, Das, Moupali, Donnell, Deborah, Duerr, Ann, Glidden, David V., Hughes, James P., Murray, Jeffrey, Robertson, Michael N., Zinserling, Joerg, Lau, Joseph, Miller, Veronica, Pottinger, Yen, Lehnert, Regine, Mastro, Timothy D., Grinsztejn, Beatriz, Tchelidze, Tamar, and Baeten, Jared

Subjects
HIV prevention, HIV infections, PRE-exposure prophylaxis, HIV, CLINICAL trials, AIDS vaccines
Abstract

Standard‐of‐care HIV pre‐exposure prophylaxis (PrEP) is highly efficacious, but uptake of and persistence on a daily oral pill is low in many settings. Evaluation of alternate PrEP products will require innovation to avoid the unpractically large sample sizes in noninferiority trials. We propose estimating HIV incidence in people not on PrEP as an external counterfactual to which on‐PrEP incidence in trial subjects can be compared. HIV recent infection testing algorithms (RITAs), such as the limiting antigen avidity assay plus viral load used on specimens from untreated HIV positive people identified during screening, is one possible approach. Its feasibility is partly dependent on the sample size needed to ensure adequate power, which is impacted by RITA performance, the number of recent infections identified, the expected efficacy of the intervention, and other factors. Screening sample sizes to support detection of an 80% reduction in incidence for 3 key populations are more modest, and comparable to the number of participants in recent phase III PrEP trials. Sample sizes would be significantly larger in populations with lower incidence, where the false recency rate is higher or if PrEP efficacy is expected to be lower. Our proposed counterfactual approach appears to be feasible, offers high statistical power, and is nearly contemporaneous with the on‐PrEP population. It will be important to monitor the performance of this approach during new product development for HIV prevention. If successful, it could be a model for preventive HIV vaccines and prevention of other infectious diseases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Reply to Richie and Villasante

Author

Duerr, Ann, Huang, Yunda, Buchbinder, Susan, Coombs, Robert W., Sanchez, Jorge, del Rio, Carlos, Casapia, Martin, Santiago, Steven, Huang, Ying, Gilbert, Peter, Corey, Lawrence, and Robertson, Michael N.

Published
2013
Full Text
View/download PDF

21. Safety and Immunogenicily of a Replication-Incompetent Adenovirus Type 5 HIV-1 Clade B Gag/pol/nef Vaccine in Healthy Adults

Author

Priddy, Frances H., Brown, Deborah, Kublin, James, Monahan, Kathleen, Wright, David P., Lalezari, Jacob, Santiago, Steven, Marmor, Michael, Lally, Michelle, Novak, Richard M., Brown, Stephen J., Kulkarni, Priya, Dubey, Sheri A., Kierstead, Lisa S., Casimiro, Danilo R., Mogg, Robin, DiNubile, Mark J., Shiver, John W., Leavitt, Randi Y., Robertson, Michael N., Mehrotra, Devan V., and Quirk, Erin

Published
2008
Full Text
View/download PDF

22. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Author

Eron, Joseph J, Jr, Rockstroh, Jürgen K, Reynes, Jacques, Andrade-Villanueva, Jaime, Ramalho-Madruga, Jose Valdez, Bekker, Linda-Gail, Young, Benjamin, Katlama, Christine, Gatell-Artigas, Jose Maria, Arribas, Jose R, Nelson, Mark, Campbell, Havilland, Zhao, Jing, Rodgers, Anthony J, Rizk, Matthew L, Wenning, Larissa, Miller, Michael D, Hazuda, Daria, DiNubile, Mark J, Leavitt, Randi, Isaacs, Robin, Robertson, Michael N, Sklar, Peter, and Nguyen, Bach-Yen

Published
2011
Full Text
View/download PDF

24. Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine

Author

Molina, Jean-Michel, primary, Yazdanpanah, Yazdan, additional, Afani Saud, Alejandro, additional, Bettacchi, Christopher, additional, Chahin Anania, Carolina, additional, Klopfer, Stephanie O., additional, Grandhi, Anjana, additional, Eves, Karen, additional, Hepler, Deborah, additional, Robertson, Michael N., additional, Hwang, Carey, additional, Hanna, George J., additional, and Correll, Todd, additional

Published
2021
Full Text
View/download PDF

27. Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.

Author

Molina, Jean-Michel, Yazdanpanah, Yazdan, Afani Saud, Alejandro, Bettacchi, Christopher, Chahin Anania, Carolina, Klopfer, Stephanie O., Grandhi, Anjana, Eves, Karen, Hepler, Deborah, Robertson, Michael N., Hwang, Carey, Hanna, George J., and Correll, Todd

Published
2022
Full Text
View/download PDF

28. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

Author

Frahm, Nicole, DeCamp, Allan C., Friedrich, David P., Carter, Donald K., Defawe, Olivier D., Kublin, James G., Casimiro, Danilo R., Duerr, Ann, Robertson, Michael N., Buchbinder, Susan P., Huang, Yunda, Spies, Gregory A., Rosa, Stephen C., and McElrath, M. Juliana

Subjects
HIV (Viruses) -- Prevention -- Health aspects -- Research, T cells -- Physiological aspects -- Research, AIDS vaccines -- Health aspects -- Research, Health care industry
Abstract

Recombinant viruses hold promise as vectors for vaccines to prevent infectious diseases with significant global health impacts. One of their major limitations is that preexisting anti-vector neutralizing antibodies can reduce T cell responses to the insert antigens; however, the impact of vector-specific cellular immunity on subsequent insert-specific T cell responses has not been assessed in humans. Here, we have identified and compared adenovirus-specific and HIV-specific T cell responses in subjects participating in two HIV-1 vaccine trials using a vaccine vectored by adenovirus serotype 5 (Ad5). Higher frequencies of pre-immunization adenovirus-specific CD [4.sup.+] T cells were associated with substantially decreased magnitude of HIV-specific CD [4.sup.+] T cell responses and decreased breadth of HIV-specific CD [8.sup.+] T cell responses in vaccine recipients, independent of type-specific preexisting Ad5-specific neutralizing antibody titers. Further, epitopes recognized by adenovirus-specific T cells were commonly conserved across many adenovirus serotypes, suggesting that cross-reactivity of preexisting adenovirus-specific T cells can extend to adenovirus vectors derived from rare serotypes. These findings provide what we believe to be a new understanding of how preexisting viral immunity may impact the efficacy of vaccines under current evaluation for prevention of HIV, tuberculosis, and malaria., Introduction Vaccines offer the most effective and durable interventions for the prevention of infectious diseases. Classic approaches to developing highly efficacious vaccines for major global health threats, including HIV, malaria, [...]

Published
2012
Full Text
View/download PDF

30. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Author

Buchbinder, Susan P, Mehrotra, Devan V, Duerr, Ann, Fitzgerald, Daniel W, Mogg, Robin, Li, David, Gilbert, Peter B, Lama, Javier R, Marmor, Michael, del Rio, Carlos, McElrath, M Juliana, Casimiro, Danilo R, Gottesdiener, Keith M, Chodakewitz, Jeffrey A, Corey, Lawrence, and Robertson, Michael N

Published
2008
Full Text
View/download PDF

32. Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial

Author

Zhdanov, Konstantin, Isakov, Vasily, Burnevich, Eduard, Kizhlo, Svetlana, Bakulin, Igor, Pokrovsky, Vadim, Liang, Liwen, Hwang, Peggy, Talwani, Rohit, Haber, Barbara A, and Robertson, Michael N

Subjects
therapy, placebo, virus diseases, hepatitis C, viral drug resistance, Evidence and Research [Hepatic Medicine], Original Research, Russia
Abstract

Konstantin Zhdanov,1 Vasily Isakov,2 Eduard Burnevich,3 Svetlana Kizhlo,4 Igor Bakulin,5 Vadim Pokrovsky,6 Liwen Liang,7 Peggy Hwang,7 Rohit Talwani,7 Barbara A Haber,7 Michael N Robertson7 1Military Medical Academy n.a. S.M. Kirov, St. Petersburg, Russia; 2Department of Gastroenterology & Hepatology, Federal Research Centre of Nutrition, Biotechnology and Food Safety, Moscow, Russia; 3I.M. Sechenov First Moscow State Medical University, Moscow, Russia; 4City Center for AIDS and Infectious Diseases Treatment and Prophylaxis, St. Petersburg, Russia; 5I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation, St. Petersburg, Russia; 6Department of AIDS, Central Research Institute of Epidemiology, Moscow, Russia; 7Merck & Co., Inc., Kenilworth, NJ, USACorrespondence: Barbara A HaberMerck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USATel +1 267-305-3729Email barbara.haber@merck.comPurpose: Hepatitis C virus (HCV) infection is a major healthcare concern in Russia, where almost 5 million individuals are viremic. Elbasvir/grazoprevir is a fixed-dose combination therapy for the treatment of HCV genotype 1 and genotype 4 infection. The present analysis aimed to assess the safety and efficacy of elbasvir/grazoprevir in individuals with HCV infection enrolled at Russian study sites in the C-CORAL study.Patients and Methods: C-CORAL (Protocol PN-5172-067; NCT02251990) was a Phase 3, placebo-controlled, double-blind study conducted throughout Asia and Russia. Treatment-naive participants with chronic HCV infection were randomly assigned to receive immediate or deferred treatment with elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks. Participants in the immediate-treatment group received elbasvir/grazoprevir for 12 weeks, and those in the deferred-treatment group received placebo for 12 weeks, followed by open-label elbasvir/grazoprevir for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after completion of therapy (SVR12).Results: One hundred and nineteen Russian participants were randomized (immediate-treatment group, n=88; deferred-treatment group, n=31). Most participants were white (99%) with HCV genotype 1b infection (97%) and mild-to-moderate (F0–F2) fibrosis (70%). SVR12 was achieved by 98.9% participants in the immediate-treatment group and by 100% of those receiving deferred elbasvir/grazoprevir in the deferred-treatment group. One participant relapsed with nonstructural protein 5A (NS5A) L28M and Y93H resistance-associated substitutions at baseline and at time of failure. Drug-related adverse events were reported by 19% of participants receiving elbasvir/grazoprevir in the immediate-treatment group and by 16% of those receiving placebo in the deferred-treatment group. No serious adverse event or deaths occurred, and no participant discontinued treatment owing to an adverse event.Conclusion: Elbasvir/grazoprevir for 12 weeks was highly effective in treatment-naive Russian individuals with HCV genotype 1b infection.Keywords: hepatitis C, therapy, placebo, Russia, viral drug resistance

Published
2020

35. Efficacy and safety of elbasvir/grazoprevir in treatment‐naive Chinese adults with hepatitis C virus infection: A randomized trial

Author

Wei, Lai, primary, Jia, Ji Dong, additional, Duan, Zhong Ping, additional, Wang, Fu Sheng, additional, Niu, Jun Qi, additional, Xie, Wen, additional, Huang, Wen Xiang, additional, Zhang, Ming Xiang, additional, Huang, Yan, additional, Wang, Mao Rong, additional, Wu, Shan Ming, additional, Zhao, Ying Ren, additional, Jia, Zhan Sheng, additional, Zhao, Xu Min, additional, Mu, Sheng Mei, additional, Liang, Li Wen, additional, Wang, Zaiqi, additional, Puenpatom, Amy, additional, Hwang, Peggy, additional, Robertson, Michael N., additional, Ingravallo, Paul, additional, Asante‐Appiah, Ernest, additional, Wei, Bo, additional, Evans, Barbara, additional, Hanna, George J., additional, and Talwani, Rohit, additional

Published
2020
Full Text
View/download PDF

37. Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study

Author

Asselah, Tarik, primary, Pol, Stanislas, additional, Hezode, Christophe, additional, Loustaud‐Ratti, Veronique, additional, Leroy, Vincent, additional, Ahmed, Si Nafa Si, additional, Ozenne, Violaine, additional, Bronowicki, Jean‐Pierre, additional, Larrey, Dominique, additional, Tran, Albert, additional, Alric, Laurent, additional, Nguyen‐Khac, Eric, additional, Robertson, Michael N., additional, Hanna, George J., additional, Brown, Deborah, additional, Asante‐Appiah, Ernest, additional, Su, Feng‐Hsiu, additional, Hwang, Peggy, additional, Hall, Jessie Durrand, additional, Guidoum, Amir, additional, Hagen, Karin, additional, Haber, Barbara A., additional, Talwani, Rohit, additional, and Serfaty, Lawrence, additional

Published
2020
Full Text
View/download PDF

41. Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy

Author

Hézode,Christophe, Kwo,Paul, Sperl,Jan, Hwang,Peggy, Long,Jianmin, Talwani,Rohit, Robertson,Michael N., Haber,Barbara A., Hézode,Christophe, Kwo,Paul, Sperl,Jan, Hwang,Peggy, Long,Jianmin, Talwani,Rohit, Robertson,Michael N., and Haber,Barbara A.

Abstract

Christophe Hézode,1 Paul Kwo,2 Jan Sperl,3 Peggy Hwang,4 Jianmin Long,4 Rohit Talwani,4 Michael N Robertson,4 Barbara A Haber4 1Service d’Hépatologie, Hôpital Henri-Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, France; 2Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA; 3Department of Hepatogastroenterology, Institut Klinické a Experimentální Medicíny (IKEM), Prague, Czech Republic; 4Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USACorrespondence: Christophe HézodeService d’Hepatologie, Hôpital Henri Mondor, 51, avenue du Maréchal de Lattre de Tassigny, Créteil 94010, FranceTel +33 14 981 2111Email christophe.hezode@aphp.frIntroduction: Some direct-acting antiviral regimens for hepatitis C virus (HCV) infection pose safety or efficacy concerns if coadministered with drugs containing ethinyl estradiol. The present analysis was conducted to examine the impact of concomitant oral contraceptive pills (OCP) or hormone replacement therapy (HRT) during treatment with elbasvir (EBR)/grazoprevir (GZR) in women with HCV genotype (GT)1 or GT4 infection.Methods: This is a post hoc, integrated retrospective analysis of female participants with HCV GT1 or GT4 infection who received EBR 50 mg/GZR 100 mg once daily for 12 weeks in phase 2/3 clinical trials. The primary end point was sustained virologic response at 12 weeks after therapy completion (SVR12). For this analysis, participants were stratified according to whether they received OCP or HRT during the original treatment study.Results: A total of 1,022 women with HCV GT1 or GT4 infection were included (receiving OCP/HRT, n=81; not receiving OCP/HRT, n=941). Most participants receiving OCP/HRT were treatment-naive (7

Published
2019

42. Antigen burden is a major determinant of human immunodeficiency virus-specific CD8+ T cell maturation state. (Major Article)

Author

Tussey, Lynda G., Nair, Ushasree Sadasivan, Bachinsky, Margaret, Edwards, Bradley H., Bakari, Janna, Grimm, Karen, Joyce, Joseph, Vessey, Rupert, Steigbigel, Roy, Robertson, Michael N., Shiver, John W., and Goepfert, Paul A.

Subjects
Immunization -- Research, Immunization of infants, HIV (Viruses) -- Physiological aspects, HIV (Viruses) -- Research, Antigens -- Evaluation, T cells -- Evaluation, T cells -- Physiological aspects, Health
Published
2003

43. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans

Author

O'Brien, Kara L., Liu, Jinyan, King, Sharon L., Sun, Ying-Hua, Schmitz, Joern E., Lifton, Michelle A., Hutnick, Natalie A., Betts, Michael R., Dubey, Sheri A., Goudsmit, Jaap, Shiver, John W., Robertson, Michael N., Casimiro, Danilo R., and Barouch, Dan H.

Subjects
T cells -- Physiological aspects -- Research -- Health aspects, AIDS vaccines -- Health aspects -- Research, Adenoviruses -- Health aspects -- Research -- Physiological aspects, HIV infection -- Risk factors -- Prevention -- Research, Biological sciences, Health
Abstract

The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study., In the phase 2b STEP efficacy study evaluating the Merck recombinant Ad5 (rAd5) vector-based HIV-1 vaccine, vaccinees with baseline Ad5-specific neutralizing antibodies showed a 2.3-fold higher rate of HIV-1 acquisition [...]

Published
2009

44. Immunization against SIVmne in macaques using multigenic DNA vaccines

Author

Mossman, Sally P., Pierce, Christopher C., Robertson, Michael N., Watson, Andrew J., Montefiori, David C., Rabin, Michael, Kuller, LaRene, Thompson, Jannelle, Lynch, John B., Morton, William R., Benveniste, Raoul E., Munn, Robert, Hu, Shiu-Lok, Greenberg, Philip, and Haigwood, Nancy L.

Published
1999

46. The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevir

Author

Guo, Zifang, primary, Caro, Luzelena, additional, Robertson, Michael N, additional, Hwang, Peggy, additional, Hoover, Patricia, additional, Wudarski, Christen, additional, Maiuri, Kristina, additional, Wang, Ying-Hong, additional, Mogg, Robin, additional, Mehrotra, Devan V, additional, Blanchard, Rebecca, additional, and Shaw, Peter M, additional

Published
2019
Full Text
View/download PDF

47. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection

Author

Wei, Lai, primary, Kumada, Hiromitsu, additional, Perumalswami, Ponni V, additional, Tanwandee, Tawesak, additional, Cheng, Wendy, additional, Heo, Jeong, additional, Cheng, Pin‐Nan, additional, Hwang, Peggy, additional, Mu, Sheng Mei, additional, Zhao, Xu Min, additional, Asante‐Appiah, Ernest, additional, Caro, Luzelena, additional, Hanna, George J, additional, Robertson, Michael N, additional, Haber, Barbara A, additional, and Talwani, Rohit, additional

Published
2019
Full Text
View/download PDF

48. Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection

Author

Lawitz, Eric, primary, Poordad, Fred, additional, Anderson, Leah J., additional, Vesay, Michelle, additional, Kelly, Michelle M., additional, Liu, Hong, additional, Gao, Wei, additional, Fernsler, Doreen, additional, Asante‐Appiah, Ernest, additional, Robertson, Michael N., additional, Hanna, George J., additional, Barr, Eliav, additional, Butterton, Joan, additional, Kowdley, Kris V., additional, Hassanein, Tarek, additional, Sahota, Amandeep, additional, Gordon, Stuart C., additional, and Yeh, Wendy W., additional

Published
2019
Full Text
View/download PDF

50. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial

Author

Foster, Graham R., primary, Agarwal, Kosh, additional, Cramp, Matthew E., additional, Moreea, Sulleman, additional, Barclay, Stephen, additional, Collier, Jane, additional, Brown, Ashley S., additional, Ryder, Stephen D., additional, Ustianowski, Andrew, additional, Forton, Daniel M., additional, Fox, Ray, additional, Gordon, Fiona, additional, Rosenberg, William M., additional, Mutimer, David J., additional, Du, Jiejun, additional, Gilbert, Christopher L., additional, Asante‐Appiah, Ernest, additional, Wahl, Janice, additional, Robertson, Michael N., additional, Barr, Eliav, additional, and Haber, Barbara, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results